Ramy Ibrahim

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

The Parker Institute for Cancer Immunotherapy is a research organization that aims to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases. The Parker Institute for Cancer Immunotherapy is based in San Francisco, CA. The private company conducts clinical trials to tackle the toughest cancers and answer the hardest questions in immunotherapy. The institute coordinates cancer research efforts between the best scientists, clinicians, and partners in the industry. The company has legal experts who help their researchers navigate the intellectual property process and turn their cancer immunotherapy discoveries into treatments. It was founded by Sean N. Parker, Adam Kolom, Michael Polansky.

MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.

Bit Bio Ltd. engages in research and experimental development on natural sciences and engineering. Its products are human-induced skeletal myocytes and glutamatergic neurons. The company was founded by Mark Kotter in 2016 and is headquartered in Cambridge, the United Kingdom.